Biogen sues company allegedly selling aducanumab copycat; J&J takes on Novartis' MS franchise
→ Biogen is taking Creative Biolabs to court, claiming the company is selling an unauthorized version of its Alzheimer’s drug aducanumab, according to Bloomberg. The controversial drug has aroused a tempest of discussion around the case Biogen has been making for an approval. Right now, though, it has yet to be submitted and the big biotech is intent on keeping sole rights to the therapy in its hands.
→ Prepping its entrance to a crowded multiple sclerosis space, J&J has filed an NDA for ponesimod — the S1P1 modulator that it’s billing as the only direct rival to Novartis’ Gilenya and Mayzent. The drug, which targets relapsing MS, beat Sanofi’s Aubagio in reducing annualized relapse rate in a Phase III.
→ Shares of Princeton, NJ-based microcap player Soligenix $SNGX popped Thursday morning after the biotech laid claim to a successful Phase III trial for SGX301, a treatment for cutaneous T cell lymphoma. Plenty of questions are likely to linger until all the data are laid out, but the biotech says they hit a p-value of 0.04 for the Composite Assessment of Index Lesion Score at 8 weeks.